-
Mashup Score: 1Immunoassays As An Imperative For Successful Gene Therapy Commercialization: Launch Challenges With Immunoassays And A Framework For Success - 1 year(s) ago
Rather than being seen as a secondary activity, immunoassays should be viewed as business-critical efforts with potential to create competitive advantage for gene therapy manufacturers.
Source: www.cellandgene.comCategories: Future of Medicine, Latest HeadlinesTweet
-
Mashup Score: 0Financial Modeling From Tufts Center Demonstrates Substantial Net Benefits To Sponsors Who Use Decentralized Clinical Trials Technology - 2 year(s) ago
To develop these insights into the business case for DCTs, researchers conducted a data-driven analysis of the value proposition and return on investment for DCTs using an expected net present value (eNPV) model. Discover the benefits from DCTs that were uncovered in this white paper.
Source: www.cellandgene.comCategories: Future of Medicine, Latest HeadlinesTweet-
Real data, real results. New research from Tufts CSDD found using the Medable platform led to shorter development cycle times, lower clinical trial screen failure rates, and fewer protocol amendments. https://t.co/0cF7lit3VB #ClinicalTrials #DecentralizedTrials #TuftsUniversity
-
-
Mashup Score: 3
Cell and gene therapy commercial success hinges on early planning to scale manufacturing and supply.
Source: www.cellandgene.comCategories: Future of Medicine, Latest HeadlinesTweet-
CGT manufacturing is a multi-step, multi-stakeholder, and multi-facility process. Learn what executives from leading CGT organizations shared with us about making strategic manufacturing decisions. https://t.co/dTxARXrfSV
-
-
Mashup Score: 3Designing A Patient-Centric Digital Ecosystem: Strategies For Cell And Gene Therapy CxOs - 3 year(s) ago
Cell and gene therapy (CGT) production is costly, complex, and high-risk; in part, because most supply chain and manufacturing processes involve multiple stakeholders and facilities. In the first article of this series we discussed how CGT adoption and success hinges on early planning to scale manufacturing and supply. This article describes strategies to enable a patient-centric digital…
Source: www.cellandgene.comCategories: Future of Medicine, Latest HeadlinesTweet-
For #CellandGeneTherapies, a well-designed #Digital ecosystem can be the key enabler to a differentiated patient and caregiver experience. Explore 4 key questions CGT CxOs should consider. https://t.co/2vL8PNONTe
-
An #immunoassay helps screen out patients at risk of immunogenicity. But what is it and why is its development surrounded by challenges. Learn more here. https://t.co/xbr6fA5nIM